RegeneRx Biopharmaceuticals, Inc. RGRX
0.00 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.161 Day range 0.161
0.0002 52-week range 0.163
- YTD
- +266.67%
- 1 year
- +450.00%
- Market cap
- 1.65K
- EPS (ttm)
- -0.71
- YTD return
- +266.67%
- 1-year return
- +450.00%
- Volume
- 252
- Avg volume
- 47
- Open
- 0.161
- Previous close
- 0.0011
- Day's range
- 0.161 – 0.161
- 52-week range
- 0.0002 – 0.163
- Earnings date
- Jan 2, 2023
6M +0.0006 (+120.00%)
Next earnings
Jan 2, 2023
Expected Jan 2, 2023. Consensus EPS estimate 0.00.
Financials — quick view
RGRX Revenue — quarterly 19.19K
RGRX Net income — quarterly -385.20K
RGRX EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 2, 2023 | Sep 1, 2022 | 0.00 | — | — | — |
| Nov 15, 2021 | Sep 1, 2021 | 0.00 | 0.00 | — | — |
| Aug 6, 2021 | Jun 1, 2021 | 0.00 | 0.00 | — | — |
News
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations 
RegeneRx Receives Stockholder Approval for Reverse Stock Split 
RegeneRx To Extend Consent Solicitation Vote 
Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis 
RegeneRx Issues Letter To Stockholders 
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome 
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement 
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement 
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome 
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
Your note
Sign in to keep a note on RGRX — it syncs with the Stock Master app.